Europe's largest bone congress opens in Bordeaux, France

March 21, 2012

An international audience of more than 4000 health professionals and researchers from around the world will meet today for the opening of the European Congress on Osteoporosis & Osteoarthritis (IOF-ECCEO12) in Bordeaux, France.

As a joint Congress of the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), IOF-ECCEO12 is the most noteworthy annual bone event in Europe. The congress will showcase the latest clinical research in close to 700 abstracts, presented in oral and poster sessions. In addition, the Congress hosts the IOF-ESCEO 2nd Pre-Clinical Symposium, a forum dedicated to translational bone research.

Professor John A. Kanis, IOF President and Co-Chair of the congress, stated "We're exceptionally pleased to welcome a broad spectrum of delegates from close to 100 countries. The Scientific Programme Committee, headed by Professors Cyrus Cooper and René Rizzoli, has organized an outstanding agenda of plenaries and sessions. Delegates can look forward to three days of stimulating discussion and exciting new science presented by the world's leading investigators."

The broad scientific programme comprises 8 plenary sessions, 12 Meet the Expert sessions, 40 oral presentations of selected abstracts, 10 special topical symposia and 6 satellite symposia. With up to 18 CME credits awarded, the Congress offers delegates valuable strategies to treat patients more effectively in their daily clinical practice.

ESCEO President and Congress Co-Chair Professor Jean-Yves Reginster commented, "It is vitally important that health professionals in Europe and around the world learn about the latest clinical advances and research findings in the prevention, diagnosis and treatment of osteoporosis and osteoarthritis. These musculoskeletal diseases pose an enormous social and health-economic burden, causing disability and loss of quality of life in millions of sufferers. It is our hope that this annual congress will arm clinicians with the information they need to prevent these diseases and provide the best possible care to their patients."

The European Congress on Osteoporosis & Osteoarthritis continues at Bordeaux's Palais des Congrès until the 24th of March. Congress abstracts are published in the journal Osteoporosis International Volume 23, Supplement 2, 2012.
-end-
ABOUT IOF

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization devoted to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members - including committees of scientific researchers, patient, medical and research societies, and industry representatives from around the globe - share a common vision of a bone healthy future without fragility fractures. IOF now represents more than 200 societies in all regions of the world. http://www.iofbonehealth.org

ABOUT ESCEO

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost- conscious perception. http://www.esceo.org

International Osteoporosis Foundation

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.